Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

"In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026," The Danish company said in its full-year.

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... in 2025 to create additional capacity “across the supply chain.” Last year, Novo said it planned to spend some 45 billion kroner ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Scope 3 emissions - which include those from all suppliers in a company's supply chain - account for 96% of Novo's overall total. Novo Nordisk's plans to cut emissions include converting to lower ...

Novo Nordisk (NYSE:NVO) A/S ... creates a significant barrier to entry for potential competitors. However, supply constraints have been a recurring challenge for the company and the broader ...

Novo Nordisk expects sales growth to slow this ... but in order to secure supply chain readiness, it now expects to file for the first regulatory approval of CagriSema during the first quarter ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter ... citing the need "to secure supply-chain readiness," which UBS said compares to its previous expectation of a late 2025 submission.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation ... previous expectation of end-2025 in order to secure supply chain readiness. Sponsored Bank Accounts Two Novo shareholders ...